Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· May 17, 2026

This billionaire says the market may be in for a ‘breathtaking’ correction — but he’s still buying AI stocks. Here’s why

View original at finance.yahoo.com
“Jones first rose to prominence after he predicted the 1987 Black Monday crash, when the Dow fell 508 points in one day (2). That day, the New York Stock Exchange lost more than $500 billion in market capitalization — the largest decline since 1914. But while investors and the media scrambled, Jones shorted the market and profited an estimated $100 million (3).”
Verbatim excerpt from the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The share of the economy devoted to AI investment is nearly a third greater than the share devoted to internet-related investments during the dot-com bubble, implying the AI bubble risk could be worse.

    60% confidence
  • Claude in January 2026 is the equivalent of when Microsoft came out in 1981 — marking the early stage of an AI revolution analogous to the PC era.

    60% confidence
  • Transformative technological shifts and productivity miracles typically last four to five and a half years, and the current AI cycle is approximately 50–60% complete.

    60% confidence
  • The market will experience breathtaking corrections at some point during the AI cycle.

    60% confidence
  • The AI bull market likely has another year or two to run before a major peak or correction.

    60% confidence
  • The current AI moment is comparable to 1995, when commercial internet use exploded alongside the launch of Windows 95.

    60% confidence
  • Governments should step in with regulations on AI due to long-term risks of the technology becoming dangerous.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com